Please assess the completion status of the following clinical trial:

Trial Title: Sisonke (Together): OPEN LABEL TRIAL COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Age 18 and older~* Health care worker in the private or public service~* The President and Deputy President of South Africa\* (The President and Deputy President of South Africa have been included in the protocol to address the issue of vaccine hesitancy. )~* Willingness and ability to comply vaccination plan and other study procedures.~* Capable of giving electronic or personal signed informed consent as described in Appendix 5, which includes compliance with the requirements in this protocol.~Inclusion criteria for the sub-cohort~* Age 18 and older~* Health care worker in the private or public service~* Willingness and ability to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures, with follow-up at an ENSEMBLE site.~* Capable of giving electronic or personal signed informed consent as described in Appendix 5, which includes compliance with the requirements in this protocol.~Exclusion criteria~* Any significant acute or chronic medical condition, situation or circumstance that in the opinion of the PI/designee makes the participant unsuitable for participation in the study, or jeopardises the safety or rights of the participant~* Participant reports being pregnant at time of enrolment, planning conception within 3 months.~* Participants who report breastfeeding at the time of enrolment will be excluded.~* Current participation in any other research studies that would interfere with the objectives of this study. The determination of whether participation in another study would be exclusionary for a given participant will be made by the PI/designee.~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.~* Participants who have experienced major venous and arterial thrombosis occurring with thrombocytopenia following vaccination with any COVID-19 vaccine should not enrol in Sisonke.~* Participants with a history of heparin-induced thrombocytopenia.~Note:~• Vaccination within 14-90 days with other COVID19 or non-specific vaccines are not exclusionary but should be discussed with study PI or designee.~Conditions of interest:~We note that international reports of VITT have not identified a risk factor, nor does there appear to be any prothrombotic state that indicates a risk factor for this immune response.~Nevertheless, the Sisonke study will enrol participants with chronic history of severe clotting disorders only after consultation and approval of the study Protocol Safety Review Team (PSRT).~We have identified certain specific conditions of special interest such as:~* cerebral venous sinus thrombosis,~* antiphospholipid syndrome~* Individuals on therapeutic anticoagulants for current or previous arterial or venous thrombosis or embolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 105 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete